SNX-5422 + carboplatin + paclitaxel

SNX-5422 is an oral HSP90 inhibitor that has been studied in combination with carboplatin and paclitaxel for the treatment of advanced lung cancers, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This combination has shown promising results in clinical trials. ## Clinical Development The combination has been evaluated in a phase 1, open-label, multicenter study to assess its safety and efficacy. In this study, SNX-5422 was administered at doses of 50, 75, or 100 mg/m² every other day for 21 days in a 28-day cycle for up to 4 cycles, while carboplatin (AUC 5) and paclitaxel (175 mg/m²) were given once every 3 weeks for up to 6 courses[1][4]. The maximum tolerated dose of SNX-5422 in this combination was determined to be 100 mg/m²[1]. After the combination treatment phase, patients who achieved at least stable disease continued with SNX-5422 monotherapy maintenance at 100 mg/m² every other day for 21 days in a 28-day cycle[1][4]. ## Efficacy Results In patients with NSCLC, the combination showed promising efficacy: - 33% (6/18) of evaluable NSCLC patients achieved partial response - 56% (10/18) had stable disease - 11% (2/18) experienced progressive disease[1] In another study with 19 evaluable NSCLC patients: - 37% (7/19) achieved partial response - 58% (11/19) had stable disease - 5% (1/19) experienced progressive disease[4] Notably, patients who remained on single-agent SNX-5422 maintenance therapy for ≥2 months had cancers that were enriched for oncogenic drivers, including KRAS mutations, EGFR exon 20 mutations, HER2 mutations, and RET fusions[1]. ## Safety Profile The combination was generally well-tolerated. The most common treatment-related adverse events included: - Diarrhea (26% grade 3/4 during combination, 15% during maintenance) - Nausea (9% grade 3/4 during combination, 0% during maintenance)[1] - Other common adverse events included fatigue, alopecia, and vomiting, with most events being grade 1/2[4] Four patients experienced grade 3 dose-limiting toxicities possibly related to at least one agent in the combination: diarrhea, increased liver enzymes, nausea/vomiting/diarrhea, and peripheral sensory neuropathy[4]. ## Mechanism of Action SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small-molecule inhibitor of heat shock protein 90 (HSP90)[7][8]. HSP90 is a molecular chaperone that plays a crucial role in the folding, stability, and function of various client proteins, many of which are involved in oncogenic signaling pathways. By inhibiting HSP90, SNX-5422 can potentially disrupt multiple cancer-driving pathways simultaneously. Carboplatin is a platinum-based chemotherapy agent that forms DNA adducts, interfering with DNA replication and transcription. Paclitaxel is a taxane that stabilizes microtubules, preventing their disassembly and thereby disrupting cell division. The combination of these three agents with different mechanisms of action provides a multi-targeted approach to cancer treatment, which may explain its promising efficacy in clinical trials.